Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China

OBJECTIVE: In frst-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC), the ORIENT-11 study demonstrated a signifcant progression-free survival and overall survival for sintilimab plus chemotherapy in comparison with chemotherapy alone. But the cost-effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Huiqin, Wang, Ying, He, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801637/
https://www.ncbi.nlm.nih.gov/pubmed/36581793
http://dx.doi.org/10.1186/s13561-022-00410-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801637/
https://www.ncbi.nlm.nih.gov/pubmed/36581793
http://dx.doi.org/10.1186/s13561-022-00410-x

Ejemplares similares